A clinical trial to determine if Varoglutamstat (PQ912) is effective in slowing effects of Alzheimer's Disease
Principal Investigator
Sudha Seshadri
Floyd Jones
210-450-3158
jonesfa@uthscsa.edu
Diagnosed with Mild Cognitive Impairment due to AD or Mild probable AD.
Have had an MRI w/in the Past Six Months
Have a study partner who has frequent interaction with the participant (3-4 times per week) and can accompany the participant to all visits.
Have been diagnosed with a disease known to cause dementia including (but not limited to) Parkinson's Disease, Huntington disease, Lewy Body Disease, or AIDS.
Have a mental illness judged to be not well controlled in the opinion of the PI.
Medical Contraindications to undergoing an MRI or Lumbar Puncture.
Have a medical condtion determined to be not well controlled on medication in the opinion of the PI.
Arm | Description | Intervention |
---|---|---|
600 mg | First 4 weeks 150 mg BID, week 5-8 300 mg BID, week 9-24 600 mg BID | PQ912 150 mg tablets Other names:
|
150 mg | 24 weeks on 150 mg BID | PQ912 150 mg tablets Other names:
|
300 mg | First 4 weeks 150 mg BID, week 5-24 300 mg BID | PQ912 150 mg tablets Other names:
|
Placebo | Placebo tablets to mimic PQ912 150 mg tablets |